Boro Dropulic has a PhD from the University of Western Australia and an MBA from Johns Hopkins University. He has more than 30 years of leadership and experience in the design, development, manufacturing, clinical translation, regulation, clinical implementation and commercialization of lentiviral vector technology. After a few years as an academic, he founded the company that developed the first FDA-approved gene therapy product.
Seeing the need for improved business models to support the accessibility and affordability of gene therapy products, Boro co-founded Caring Cross, where he currently serves as CEO.